BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
4.300
-0.210 (-4.66%)
At close: Apr 28, 2026, 4:00 PM EDT
4.300
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
BioAtla Employees
BioAtla had 41 employees as of December 31, 2025. The number of employees decreased by 20 or -32.79% compared to the previous year.
Employees
41
Change (1Y)
-20
Growth (1Y)
-32.79%
Revenue / Employee
$48,780
Profits / Employee
-$1,453,829
Market Cap
7.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Processa Pharmaceuticals | 12 |
| TransCode Therapeutics | 12 |
| NuCana | 12 |
| MetaVia | 8 |
| Indaptus Therapeutics | 5 |
| Creative Medical Technology Holdings | 4 |
| Silo Pharma | 3 |
| PharmaCyte Biotech | 2 |
BCAB News
- 4 weeks ago - BioAtla Announces Share Consolidation - GlobeNewsWire
- 4 weeks ago - BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - GlobeNewsWire
- 4 months ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 5 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 5 months ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 6 months ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 6 months ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire